Satish K Dhingra

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4259737/publications.pdf

Version: 2024-02-01

		623734	996975
15	1,086	14	15
papers	citations	h-index	g-index

17	17	17	1330
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based combination therapies. Nature Communications, 2016, 7, 11553.	12.8	208
2	Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nature Communications, 2018, 9, 3314.	12.8	183
3	Structure and drug resistance of the Plasmodium falciparum transporter PfCRT. Nature, 2019, 576, 315-320.	27.8	123
4	Adaptive evolution of malaria parasites in French Guiana: Reversal of chloroquine resistance by acquisition of a mutation in pfcrt. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 11672-11677.	7.1	101
5	Plasmodium falciparum K13 mutations in Africa and Asia impact artemisinin resistance and parasite fitness. ELife, 2021, 10, .	6.0	85
6	A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine. MBio, 2017, 8, .	4.1	82
7	Balancing drug resistance and growth rates via compensatory mutations in the <scp>P</scp>lasmodium falciparum chloroquine resistance transporter. Molecular Microbiology, 2015, 97, 381-395.	2.5	47
8	Plasmodium falciparum resistance to piperaquine driven by PfCRT. Lancet Infectious Diseases, The, 2019, 19, 1168-1169.	9.1	46
9	Identification and Mechanistic Understanding of Dihydroorotate Dehydrogenase Point Mutations in Plasmodium falciparum that Confer in Vitro Resistance to the Clinical Candidate DSM265. ACS Infectious Diseases, 2019, 5, 90-101.	3.8	43
10	Global Spread of Mutant PfCRT and Its Pleiotropic Impact on Plasmodium falciparum Multidrug Resistance and Fitness. MBio, 2019, 10, .	4.1	35
11	Evolution of Fitness Cost-Neutral Mutant PfCRT Conferring P. falciparum 4-Aminoquinoline Drug Resistance Is Accompanied by Altered Parasite Metabolism and Digestive Vacuole Physiology. PLoS Pathogens, 2016, 12, e1005976.	4.7	34
12	Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study. Lancet Infectious Diseases, The, 2021, 21, 1713-1724.	9.1	32
13	Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	30
14	Evidence for Regulation of Hemoglobin Metabolism and Intracellular Ionic Flux by the Plasmodium falciparum Chloroquine Resistance Transporter. Scientific Reports, 2018, 8, 13578.	3.3	24
15	Evidence for the early emergence of piperaquine-resistant Plasmodium falciparum malaria and modeling strategies to mitigate resistance. PLoS Pathogens, 2022, 18, e1010278.	4.7	13